Investors

OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities.
More>>
Featured Reports
2016 Annual Report on Form 10-K - PDF 2016 Annual Report on Form 10-K
Fact Sheet - PDF Fact Sheet
OSUR (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$20.49
Change (%) Stock is Down 0.37 (1.77%)
Volume232,810
Data as of 08/23/17 3:05 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
08/02/17OraSure Announces 2017 Second Quarter Financial Results
BETHLEHEM, Pa., Aug. 02, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its consolidated financial results for the three and six months ended June 30, 2017. Financial Highlights Consolidated net revenues for the second quarter of 2017 were $40.2 million, a 28% increase from the second quarter of 2016. Net product revenues were $39.1 million, representing a 42% increase over the... 
Printer Friendly Version
08/01/17OraSure Technologies to Present at the Canaccord Genuity 37th Annual Growth Conference
BETHLEHEM, Pa., Aug. 01, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Canaccord Genuity 37th Annual Growth Conference in Boston, Massachusetts.  The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak on August 10, 2017, at approximately 8:00 AM Ea... 
Printer Friendly Version
07/24/17OraQuick® HIV Self-Test Selected for Next Phase of STAR Project for HIV Self-Testing in Africa (revised July 27, 2017)
~Phase II of STAR Project Expected to Deploy 4 Million Additional HIV Self-Tests~ BETHLEHEM, Pa., July 24, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that its OraQuick® HIV Self-Test (HIVST) has been selected by UNITAID and Population Services International (PSI) for use in Phase II of the HIV Self-Testing Africa (STAR) Project. The STAR Project Phase II, beginning in Q4 of 201... 
Printer Friendly Version
07/21/17OraSure Technologies Receives World Health Organization Prequalification of OraQuick® HIV Self-Test
WHO Prequalification will enable procurement of OraQuick® HIV Self-Test with monies from global public health funding sources BETHLEHEM, Pa., July 21, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that its OraQuick® HIV Self-Test (HIVST) has been Prequalified by the World Health Organization (WHO). The OraQuick HIV Self-Test is a rapid, point-of-care test that allows an individual... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources



Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Financial Tear Sheet